Pieris Pharmaceuticals, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Palvella Therapeutics announced strong Q2 2026 financial results, highlighting significant progress in its QTORIN rapamycin NDA submission for microcystic lymphatic malformations and advancement of other pipeline programs.
Palvella Therapeutics, Inc. shared a corporate presentation on July 14, 2026, detailing advancements in its QTORIN platform and pipeline for rare skin diseases.
Palvella Therapeutics, Inc. has appointed Matthew Pauls to its Board of Directors, expanding the board to eight members.
Palvella Therapeutics stockholders approved an increase in equity incentive plan shares and ratified director elections at the 2026 Annual Meeting.
Palvella Therapeutics announced positive clinical data from Phase 3 SELVA and Phase 2 TOIVA studies for QTORIN rapamycin at the ISSVA World Congress 2026, supporting its potential as a first-in-disease therapy for rare vascular malformations.
Palvella Therapeutics announced new data from its Phase 2 TOIVA trial of QTORIN rapamycin for cutaneous venous malformations, showing significant improvement in bleeding and high patient satisfaction.
Palvella Therapeutics, Inc. has received Nasdaq approval to transfer its common stock listing to the Nasdaq Global Market, effective May 13, 2026.
Palvella Therapeutics announced its first quarter 2026 financial results, highlighting progress in its QTORIN rapamycin program for microcystic lymphatic malformations and providing updates on its broader pipeline development.
Palvella Therapeutics, Inc. has appointed Dr. John Doux to its Board of Directors, expanding the board to seven members.
Palvella Therapeutics reports positive Phase 3 data for its lead candidate and outlines a path toward NDA submission in late 2026.
Palvella Therapeutics announced positive Phase 3 results for QTORIN rapamycin in microcystic LMs, strengthened its balance sheet with a $230M financing, and advanced multiple rare disease programs.
Palvella Therapeutics, Inc. announced a public offering of 1.6 million shares of common stock at $125.00 per share, aiming to raise approximately $187.3 million in net proceeds to fund its development programs and for general corporate purposes.
Palvella Therapeutics, Inc. announced a preliminary cash, cash equivalents, and marketable securities balance of approximately $55.9 million as of December 31, 2025.
Palvella Therapeutics announced highly statistically significant topline results from its Phase 3 SELVA study for QTORIN 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations, paving the way for an NDA filing.
Palvella Therapeutics announced positive topline results from its Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations.
Palvella Therapeutics highlights significant progress in its QTORIN platform, with late-stage clinical data expected and an expanded pipeline for rare skin diseases and vascular malformations.
Palvella Therapeutics, Inc. highlights significant progress in its rare disease pipeline, including positive Phase 2 data for cutaneous venous malformations and anticipated Phase 3 results for microcystic lymphatic malformations in March 2026.
Palvella Therapeutics announced positive topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for cutaneous venous malformations.
Palvella Therapeutics announced its third quarter 2025 financial results and provided a corporate update, highlighting progress in its rare skin disease pipeline and extending its cash runway into the second half of 2027.
Palvella Therapeutics announces a new product candidate, QTORIN pitavastatin, targeting Disseminated Superficial Actinic Porokeratosis (DSAP), a serious rare skin disease with no FDA-approved therapies.
Palvella Therapeutics announced the expansion of its QTORIN 3.9% rapamycin anhydrous gel development program into Clinically Significant Angiokeratomas, a rare lymphatic disease with no FDA-approved therapies.
Palvella Therapeutics details accelerated U.S. launch plans for its lead QTORIN rapamycin gel and outlines key clinical milestones for rare genetic skin diseases.
Palvella Therapeutics announced its second quarter 2025 financial results and provided a corporate update, highlighting progress in its Phase 3 SELVA and Phase 2 TOIVA trials and an extended cash runway.
Palvella Therapeutics, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all proposals, including the election of Class II directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of executive compensation, were passed.
Palvella Therapeutics reports Q1 2025 financial results, highlighting the exceeding of the enrollment target for its Phase 3 SELVA trial and a cash runway into the second half of 2027.
Palvella Therapeutics announces its full year 2024 financial results, highlighting progress in clinical trials and pipeline expansion following a merger and private placement.
Palvella Therapeutics, Inc. released a corporate presentation on March 4, 2025, to be used in investor meetings.
Palvella Therapeutics, Inc. released a corporate presentation on January 13, 2025, for use in investor meetings.
Palvella Therapeutics has finalized its merger with Pieris Pharmaceuticals, launching as a publicly traded rare disease biopharmaceutical company with a robust financial backing.
Pieris Pharmaceuticals stockholders approved a merger with Palvella Therapeutics, an increase in authorized shares, and a new equity incentive plan at a special meeting on December 11, 2024.